A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

This publication has 19 references indexed in Scilit:

• Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
  American Heart Journal, 2004
• Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic Events
  Stroke, 2004
• Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes
  Circulation, 2003
• Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease
  Circulation, 2003
• Scientific and therapeutic advances in antiplatelet therapy
  Nature Reviews Drug Discovery, 2003
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
  BMJ, 2002
• Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials
  Heart, 2001
• Peripheral arterial disease - epidemiological aspects
  Vascular Medicine, 2001
• Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
  New England Journal of Medicine, 1998
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
  The Lancet, 1996